Evidence review
Is NAD+ a Peptide? What It Actually Is, and Why the Label Matters
No. NAD+ is a dinucleotide coenzyme with a phosphate backbone — no amino acids, no peptide bonds. Here's the formula, and why the distinction matters.
On this page
No. NAD+ is not a peptide, and it is not a close call — the two are different classes of molecule built from different parts. The confusion is entirely reasonable, though, because NAD+ is sold on peptide websites, injected the way peptides are injected, and priced alongside them. Including, to be fair, on this site.
What NAD+ actually is
NAD+ stands for nicotinamide adenine dinucleotide. The name contains the answer: a dinucleotide. It is two nucleotides — one built on nicotinamide, one on adenine — joined through a pair of phosphate groups.
Its molecular formula is C21H27N7O14P2, with a molecular weight of about 6632.
Look at the end of that formula: P2. Two phosphorus atoms. That single detail settles the question, because peptides do not contain phosphate backbones. A peptide is a chain of amino acids linked by amide bonds — the "peptide bonds" the class is named for. Carbon, hydrogen, nitrogen, oxygen, occasionally sulfur. Not phosphorus in the backbone.
For contrast, here is a real peptide drug sold in the same category: semaglutide, formula C187H291N45O59, molecular weight about 4,1143. No phosphorus, and roughly six times the mass. That is what a peptide looks like on paper.
Two different classes of molecule
| NAD+ | Semaglutide (a peptide) | |
|---|---|---|
| Molecular class | Dinucleotide coenzyme | Peptide |
| Formula | C21H27N7O14P2 | C187H291N45O59 |
| Molecular weight | ~663 Da | ~4,114 Da |
| Built from | Two nucleotides joined by phosphates | A chain of amino acids |
| Bond type in the backbone | Phosphodiester | Amide (peptide) bonds |
| Contains phosphorus | Yes — two atoms | No |
| Biological role | Carries electrons in redox reactions; enzyme substrate | Binds a receptor and signals |
What NAD+ does, since that is the other half of the confusion
Peptides in this market are mostly signaling molecules: they bind a receptor and tell a cell to do something. Semaglutide binds the GLP-1 receptor. Sermorelin binds the growth-hormone-releasing-hormone receptor. That receptor-and-signal model is the mental template most people bring to "peptide."
NAD+ does not work that way at all. It is a coenzyme — a molecule that participates directly in chemical reactions as a carrier. Its central role is in redox reactions, shuttling electrons by cycling between its oxidized form (NAD+) and its reduced form (NADH), and it is also consumed as a substrate by several classes of signaling enzyme. A 2021 review in Nature Reviews Molecular Cell Biology, titled "NAD+ metabolism and its roles in cellular processes during ageing," describes it in exactly those terms1.
So the difference is not just structural. A peptide drug is a message. NAD+ is a working part.
Why the distinction has practical consequences
It would be easy to file this under trivia. It is not, because "it's a peptide" carries a set of assumptions that do not transfer.
Size and delivery. At 663 daltons NAD+ is a small molecule by peptide standards, and size governs how a compound can be delivered. Peptide-specific reasoning about why something must be injected does not automatically apply to a molecule one-sixth the mass.
Stability and handling. Peptide storage guidance exists because peptides denature and are cleaved by proteases. NAD+ has its own stability behavior, driven by different chemistry. Applying peptide reconstitution rules to it by analogy is reasoning from a category error.
Regulatory framing. The compounding rules and bulk-substance debates that govern peptide products turn on what a substance is. NAD+ being a coenzyme rather than a peptide puts it in a different conversation from the one about peptide compounding.
Evidence transfer. This is the big one. Nothing about the trial data for a GLP-1 peptide says anything about NAD+, and vice versa. They are not siblings. Grouping them because they arrive in similar vials from similar websites is a marketing artifact, not a biological relationship.
So why is it sold with peptides?
Because "peptide" has drifted, commercially, from a chemical class into a category of product: an injectable, non-brand-name compound bought from a telehealth provider or compounding pharmacy, usually for performance, longevity or aesthetics. NAD+ fits that commercial category precisely. It fits the chemical one not at all.
This site ranks NAD+ providers for the same reason — that is where readers are shopping. Our NAD+ provider comparison reads each provider's pricing and pharmacy disclosure off its own site, the same as every other board here. Whether the compound is chemically a peptide has no bearing on whether a provider is telling you the truth about its price.
What to read next
If your actual question is whether it works, that is a separate article and a much longer answer: our NAD+ evidence review covers what the human data does and does not support. If you are comparing routes, our NAD+ nasal spray article covers that specific format, and our NAD+ dosage and side effects article covers what is published on both. NMN is the other molecule frequently confused with NAD+ — it is a precursor, not the same compound — and our NMN versus NAD+ article covers the difference.
What to take from this
NAD+ is a dinucleotide coenzyme: two nucleotides joined by phosphates, formula C21H27N7O14P2, about 663 daltons, with no amino acids and no peptide bonds in it. A peptide is a chain of amino acids joined by amide bonds, and the peptide drugs sold beside it are five to seven times heavier and contain no phosphorus. The two share a shopping category and nothing else — which matters mainly because it means evidence about one tells you nothing about the other.
Top ranked for this compound
Care Bare Rx
Not published
Tells you which drug and which format you are buying, and names all four pharmacies that fill it — more than most will.
See Care Bare Rx pricingPartner
- Pricing
- Starting-at price
- Pharmacy
- 503A pharmacy
- Labs
- Required
Advertising disclosure — we may earn a commission at no extra cost to you. See our disclosure.
Also worth knowing
Enhance MD
A clean, unhedged "compounded in accordance with federal Section 503A guidelines" claim, and a genuine choice between an injectable and a cheaper sublingual wafer format — but billing runs on a 28-day cycle, not a calendar month.
See Enhance MDPartner
Frequently asked questions
Is NAD+ a peptide?
No. NAD+ is nicotinamide adenine dinucleotide — two nucleotides joined through phosphate groups, formula C21H27N7O14P2. It contains no amino acids and no peptide bonds. A peptide is a chain of amino acids joined by amide bonds, and peptide backbones contain no phosphorus.
What kind of molecule is NAD+ then?
A coenzyme, specifically a dinucleotide. Rather than binding a receptor and sending a signal the way peptide drugs do, it participates directly in chemical reactions — carrying electrons by cycling between NAD+ and NADH, and serving as a substrate for several classes of signaling enzyme.
Why is NAD+ sold on peptide websites?
Because "peptide" has come to describe a category of product rather than a chemical class: an injectable, non-brand-name compound bought from a telehealth provider or compounding pharmacy. NAD+ fits that commercial category exactly. It does not fit the chemical one.
Does it matter whether NAD+ is a peptide?
Yes, in a few practical ways. Peptide-specific reasoning about delivery, storage stability and compounding regulation rests on peptide chemistry, and does not transfer to a coenzyme one-sixth the molecular weight. Most importantly, trial evidence about peptide drugs says nothing about NAD+ and vice versa — they are not related compounds.
Is NMN a peptide?
No. NMN — nicotinamide mononucleotide — is a single nucleotide and a precursor in the pathway that produces NAD+. Like NAD+, it is a nucleotide-derived compound rather than a chain of amino acids.
References
- Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. https://pubmed.ncbi.nlm.nih.gov/33353981/
- PubChem, National Center for Biotechnology Information (2026). NAD+ (nicotinamide adenine dinucleotide) — molecular formula and computed molecular weight. PubChem Compound Database (NCBI). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/NAD/property/MolecularWeight,MolecularFormula/JSON
- PubChem, National Center for Biotechnology Information (2026). Semaglutide — molecular formula and computed molecular weight. PubChem Compound Database (NCBI). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/semaglutide/property/MolecularWeight,MolecularFormula/JSON
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Is Compounded Tirzepatide Still Legal? What the FDA Actually Says
The FDA declared the tirzepatide shortage resolved in 2024. Here is what that actually changed for compounding pharmacies, read off the agency's own timeline.
ReadIs Compounded Semaglutide Still Legal? What the FDA Actually Says
FDA declared the semaglutide shortage resolved in February 2025 — a different timeline and court docket than tirzepatide's. Here is the agency's own record.
ReadIs Sermorelin Safe? A Direct Verdict on What the Evidence Actually Shows
Is sermorelin safe? Here's a direct verdict: what its trials found, what its post-marketing record shows, and the real gaps in the evidence that remain.
ReadIs Zepbound the Same as Tirzepatide? Brand, Molecule, and What Actually Differs
Zepbound and Mounjaro are the same molecule with different approved uses — and one covers children while the other doesn't. Here's what the labels say.
ReadTirzepatide Side Effects: What Its FDA Label and Pivotal Trials Actually Report
Tirzepatide has an FDA label with a boxed warning and real per-dose trial data. Here's what Zepbound, Mounjaro, and their pivotal trials actually reported.
ReadSermorelin Side Effects: What the Trials, the Class Label, and the Cancer Data Actually Report
Sermorelin has no current FDA label. Here are the side effects its own trials reported, the class label's warnings, and what the cancer data really shows.
Read